Scadenza: 1 February 2022
Scadenze successive:
Deadline model two-stage
Planned opening date
06 October 2021
Deadline dates
01 February 2022 17:00:00 Brussels time
06 September 2022 17:00:00 Brussels time
Topic:
Proposals should aim to develop therapies for rare diseases with no approved therapeutic option. Proposals should focus on group(s) of rare diseases with commonalities, such as shared biological features, possibly within the same and/or across different medical areas within the rare diseases landscape. Thus, proposals should not address a single disease only.
The therapies to be developed may include a broad family of therapeutic interventions such as small molecule(s), advanced therapy medicinal products, repurposing of existing medicinal products, including non-pharmacological interventions and/or their combinations, as relevant.
The topic will support proposals covering several different stages in the continuum of the innovation pathway (i.e. translational, preclinical, clinical research, validation in the clinical and/or real-world setting etc.), as relevant.
The proposals should address most of the following research activities:
- Establish multidisciplinary collaborations between all relevant stakeholders by integrating disciplines, technological developments and existing knowledge.
- Develop and utilise relevant preclinical models and/or innovative tools/technologies to: verify molecular/cellular pathways/genes that can be therapeutically targeted, increase the confidence in the targets selection and/or perform toxicity studies.
- Develop and/or execute innovative clinical trials designs for small populations and novel approaches to assess and monitor the safety and efficacy of the proposed interventions
Programma:
HORIZON-RIA HORIZON Research and Innovation Actions
Ente finanziatore:
EU
Budget complessivo:
60.00 million
Who can participate:
To be eligible for funding, applicants must be established in one of the eligible countries, i.e.:
– the Member States of the European Union, including their outermost regions;
– the Overseas Countries and Territories (OCTs) linked to the Member States;
– eligible non-EU countries:
– countries associated to Horizon Europe;
– low- and middle-income countries
Partnership: Mandatory
Status:
Closed
Quota finanziabile:
100%
Topic:
Proposals should aim to develop therapies for rare diseases with no approved therapeutic option. Proposals should focus on group(s) of rare diseases with commonalities, such as shared biological features, possibly within the same and/or across different medical areas within the rare diseases landscape. Thus, proposals should not address a single disease only.
The therapies to be developed may include a broad family of therapeutic interventions such as small molecule(s), advanced therapy medicinal products, repurposing of existing medicinal products, including non-pharmacological interventions and/or their combinations, as relevant.
The topic will support proposals covering several different stages in the continuum of the innovation pathway (i.e. translational, preclinical, clinical research, validation in the clinical and/or real-world setting etc.), as relevant.
The proposals should address most of the following research activities:
- Establish multidisciplinary collaborations between all relevant stakeholders by integrating disciplines, technological developments and existing knowledge.
- Develop and utilise relevant preclinical models and/or innovative tools/technologies to: verify molecular/cellular pathways/genes that can be therapeutically targeted, increase the confidence in the targets selection and/or perform toxicity studies.
- Develop and/or execute innovative clinical trials designs for small populations and novel approaches to assess and monitor the safety and efficacy of the proposed interventions
Who can participate:
To be eligible for funding, applicants must be established in one of the eligible countries, i.e.:
– the Member States of the European Union, including their outermost regions;
– the Overseas Countries and Territories (OCTs) linked to the Member States;
– eligible non-EU countries:
– countries associated to Horizon Europe;
– low- and middle-income countries
Programme:
HORIZON-RIA HORIZON Research and Innovation Actions
Consortium: Required
Status: Open
Total budget:
60.00 million
Funding rate:
100%
Notes:
The Commission estimates that an EU contribution of around EUR 8.00 million would allow these outcomes to be addressed appropriately.
The Joint Research Centre (JRC) may participate as member of the consortium selected for funding
